Giovanni Martinelli

Research interests

Publications

• Diagnosis, prognostic factors, and assessment of ALL in adults: 2024 ELN recommendations from a European expert panel

  Blood · 2024 · https://doi.org/10.1182/blood.2023020794

• Management of ALL in adults: 2024 ELN recommendations from a European expert panel

  Blood · 2024 · https://doi.org/10.1182/blood.2023023568

• Follow-up of patients with R/R FLT3- mutation–positive AML treated with gilteritinib in the phase 3 ADMIRAL trial

  Blood · 2022 · https://doi.org/10.1182/blood.2021011583

• MDM2 inhibition: an important step forward in cancer therapy

  Leukemia · 2020 · https://doi.org/10.1038/s41375-020-0949-z

• Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial

  The Lancet Oncology · 2019 · https://doi.org/10.1016/s1470-2045(19)30150-0

• Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3 -Mutated AML

  New England Journal of Medicine · 2019 · https://doi.org/10.1056/nejmoa1902688

• Chromothripsis in acute myeloid leukemia: biological features and impact on survival

  Leukemia · 2018 · https://doi.org/10.1038/s41375-018-0035-y

• Complete Hematologic and Molecular Response in Adult Patients With Relapsed/Refractory Philadelphia Chromosome–Positive B-Precursor Acute Lymphoblastic Leukemia Following Treatment With Blinatumomab: Results From a Phase II, Single-Arm, Multicenter Study

  Journal of Clinical Oncology · 2017 · https://doi.org/10.1200/jco.2016.69.3531

• Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia

  New England Journal of Medicine · 2016 · https://doi.org/10.1056/nejmoa1509277

• International reference analysis of outcomes in adults with B-precursor Ph-negative relapsed/refractory acute lymphoblastic leukemia

  Haematologica · 2016 · https://doi.org/10.3324/haematol.2016.144311

• Blinatumomab vs historical standard therapy of adult relapsed/refractory acute lymphoblastic leukemia

  Blood Cancer Journal · 2016 · https://doi.org/10.1038/bcj.2016.84

• International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts

  Blood · 2015 · https://doi.org/10.1182/blood-2015-01-621664

• European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013

  Blood · 2013 · https://doi.org/10.1182/blood-2013-05-501569

• Genome integrity of myeloproliferative neoplasms in chronic phase and during disease progression

  Blood · 2011 · https://doi.org/10.1182/blood-2011-01-331678

• Front-line treatment of acute promyelocytic leukemia with AIDA induction followed by risk-adapted consolidation for adults younger than 61 years: results of the AIDA-2000 trial of the GIMEMA Group

  Blood · 2010 · https://doi.org/10.1182/blood-2010-03-276196

• Comparison of imatinib 400 mg and 800 mg daily in the front-line treatment of high-risk, Philadelphia-positive chronic myeloid leukemia: a European LeukemiaNet Study

  Blood · 2009 · https://doi.org/10.1182/blood-2008-12-191254

• Follicular Lymphoma International Prognostic Index 2: A New Prognostic Index for Follicular Lymphoma Developed by the International Follicular Lymphoma Prognostic Factor Project

  Journal of Clinical Oncology · 2009 · https://doi.org/10.1200/jco.2008.21.3991

• Primary diffuse large B-cell lymphoma of the breast: prognostic factors and outcomes of a study by the International Extranodal Lymphoma Study Group

  Annals of Oncology · 2007 · https://doi.org/10.1093/annonc/mdm471

• Levofloxacin to Prevent Bacterial Infection in Patients with Cancer and Neutropenia

  New England Journal of Medicine · 2005 · https://doi.org/10.1056/nejmoa044097

• Genomic and expression profiling identifies the B‐cell associated tyrosine kinase Syk as a possible therapeutic target in mantle cell lymphoma

  British Journal of Haematology · 2005 · https://doi.org/10.1111/j.1365-2141.2005.05883.x

• Clinical Activity of Rituximab in Gastric Marginal Zone Non-Hodgkin's Lymphoma Resistant to or Not Eligible for Anti–Helicobacter Pylori Therapy

  Journal of Clinical Oncology · 2005 · https://doi.org/10.1200/jco.2005.08.128

• Very young women (<35 years) with operable breast cancer: features of disease at presentation

  Annals of Oncology · 2002 · https://doi.org/10.1093/annonc/mdf039

• CXCR4 neutralization, a novel therapeutic approach for non-Hodgkin's lymphoma.

  PubMed · 2002

• Patterns of Outcome and Prognostic Factors in Primary Large-Cell Lymphoma of the Testis in a Survey by the International Extranodal Lymphoma Study Group

  Journal of Clinical Oncology · 2002 · https://doi.org/10.1200/jco.2003.11.141

• Resting and activated endothelial cells are increased in the peripheral blood of cancer patients

  Blood · 2001 · https://doi.org/10.1182/blood.v97.11.3658

Current projects

No projects listed.